Tresata Announces the Beginning of the End of Financial Crime With Free Service, BADaaS
September 08, 2021 08:00 ET
|
Tresata
CHARLOTTE, N.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Tresata announced today the launch of its Regtech Cloud with the availability of Bad Actor Discovery as a Service (BADaaS). Powered by Tresata’s...
Aite-Novarica Group Announces Winners of the 2021 Fraud & AML Impact Innovation Awards
September 08, 2021 08:00 ET
|
AITE Group
Boston, MA, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aite-Novarica Group is pleased to announce the winners of the 2021 Fraud & AML Impact Innovation Awards. The awards, which will be presented during...
Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 07:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with...
Bottomline Launches Real-Time Watchlist Screening
August 11, 2021 04:00 ET
|
Bottomline Technologies, Inc.
PORTSMOUTH, N.H., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Bottomline (NASDAQ: EPAY), a leading provider of financial technology that makes complex business payments simple, smart and secure, today...
After a Record-Breaking Q2, Acuant Announces the Addition of Video KYC for Secure Remote Onboarding and Transactions to Its Trusted Identity Platform
August 10, 2021 08:00 ET
|
Acuant
LOS ANGELES, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Acuant, the leading global Trusted Identity Platform for fraud prevention and AML compliance, announced today the addition of Video Know Your Customer...
Aptose Reports Results for the Second Quarter 2021
August 03, 2021 16:01 ET
|
Aptose Biosciences, Inc.
- Conference call and webcast at 5:00 pm EDT today - - Luxeptinib Phase 1a/b studies in AML and B cell malignancies fully enrolled at 750 mg dose - - APTO-253 Phase 1a/b study in AML / MDS treating...
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
July 21, 2021 08:00 ET
|
Aprea Therapeutics
58% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplant BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a...
Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
July 01, 2021 08:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced positive...
TigerGraph Expands Partner Ecosystem to Bring the Power of Graph to More Businesses Worldwide
June 29, 2021 09:00 ET
|
TigerGraph, Inc.
Graph Leader Grows Channel Community with Partners in Americas, Europe and Asia to Address Wide Range of Industry Use Cases REDWOOD CITY, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- TigerGraph,...
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
June 16, 2021 08:00 ET
|
Aprea Therapeutics
37% CR rate in 30 efficacy-evaluable patients BOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and...